Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence

Mark G. Lebwohl; James G. Krueger; John Y. Koo; George Han; April W. Armstrong; Bruce E. Strober; Leon H. Kircik

doi:10.36849/jdd.9739

February 1, 2026Journal of Drugs in Dermatology

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the efficacy and safety of brodalumab for managing moderate-to-severe psoriasis over eight years.
Long-term observational study design
Assessment of patient outcomes over eight years
Evaluation of tolerability and disease control
Brodalumab demonstrates high levels of disease control in patients
Well-tolerated among patients with moderate-to-severe psoriasis
Effective for those with previous biologic treatment or complex disease manifestations

Implication

Analysis shows brodalumab achieves effective disease control in patients with psoriasis, indicating its value as a treatment option.

Abstract

These findings reinforce that brodalumab is an important, well-tolerated therapeutic option for achieving high levels of disease control in patients with moderate-to-severe psoriasis, including those with prior biologic exposure or difficult-to-treat disease manifestations. .

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lebwohl et al. (2026) studied this question.

synapsesocial.com/papers/69abc1015af8044f7a4e9ad5 https://doi.org/10.36849/jdd.9739

View Full Paper

Ask AI

Bookmark

Share

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence

Key Points

Implication

Abstract

Discussion

Cite This Study

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading